Statins × cardiovascular events

TrialLancet (London, England)

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Helen M Colhoun et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 2,838 people

Randomised comparison

Reduced cardiovascular events

−37.0percentage points−52.0 to −17.0

As reported

difference −37.0 %, 95% CI −52.0 to −17.0

One number in the abstract

the abstract, start to end

cardiovascular event (rate reduction 37% [95% CI -52 to -17], p=0.001).

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
−37.0−52.0 to −17.0
StatinsCardiovascular events

Statins × cardiovascular eventshelps?replicated

unlikelylikely
0.860.85 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

1,010 papers cite itlatest 60 shown

2021
2022
2023
2024
2025
2026
pooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 15325833